Strengthening the Profitable Business Base and Growth Targets Through the Fiscal Year Ending March 2021
First written in FY2018. 4 of 13 entries say "Softened", first in FY2019. Latest entry: 2026-07-30.
Japan Tissue Engineering moved to the "Worse" side of this theme in 2019, 7 years before the typical company in this theme (2026).
The whole theme swung hardest in 2026: 3 of 8 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2026Presented a profit forecast for the fiscal year ending March 2027 and renewed the focus on achieving stable profitabilityAnnual report
「In the earnings release dated 1 May 2026, the company forecasts revenue of ¥3,070 million, up 40.6% year on year, operating profit of ¥100 million, ordinary profit of ¥110 million and net income of ¥100 million for the current fiscal year, driven by revenue growth in the regenerative medicine products, regenerative medicine contract services and LabSite businesses.」
After losses widened in the fiscal year ending March 2026, the company presented a forecast for profitability in the fiscal year ending March 2027, including revenue of ¥3,070 million and operating profit of ¥100 million, based on revenue growth in its 3 businesses. - FY2025Renewed priority on achieving stable profitability after falling back into the red following full-year profitabilityAnnual report
「Our top priority is to steadily bring these products to market, expand revenue and achieve stable profitability.」
After achieving full-year profitability in the previous fiscal year, the company posted a loss in the current fiscal year and has reaffirmed that its top priority is to achieve stable profitability by launching new products and expanding revenue. - FY2024AchievedAnnual report
「In its "Matters Concerning the Business Plan and Growth Potential" dated 9 May 2024, the company stated that it achieved profitability in the fiscal year ending March 2024 as planned under its medium-term management plan, and aims to achieve revenue of ¥5 billion and an operating margin of more than 10% in the fiscal year ending March 2026.」
The company reported that it achieved profitability in the fiscal year ending March 2024 as planned under its medium-term management plan. Meanwhile, it continues to target revenue of ¥5 billion and an operating margin of more than 10% for the fiscal year ending March 2026. - FY2024-Q1RaisedAnnual report
「With respect to the full-year earnings forecast for the fiscal year ending March 2024, the company has changed the full-year forecast for the fiscal year ending March 2024, covering the period from 1 April 2023 to 31 March 2024, announced on 27 April 2023, as follows.」
For the full-year earnings forecast for the fiscal year ending March 2024, the revenue forecast was unchanged at ¥2,749 million, while the forecasts for operating profit, ordinary profit and net income were raised from ¥83 million to ¥126 million, from ¥85 million to ¥127 million, and from ¥75 million to ¥109 million, respectively. - FY2022ReframedAnnual report
「In its "Matters Concerning the Business Plan and Growth Potential" dated 10 May 2022, the company stated that it aims to achieve profitability in the fiscal year ending March 2024, revenue of ¥5 billion and an operating margin of more than 10% in the fiscal year ending March 2026.」
After withdrawing its previous numerical plans through the fiscal year ending March 2021, the company presented new medium-term targets of achieving profitability in the fiscal year ending March 2024, and revenue of ¥5 billion and an operating margin of more than 10% in the fiscal year ending March 2026. - FY2020SoftenedAnnual report
「The company has postponed the publication of its earnings forecast for the fiscal year ending March 2021 and its numerical plans for the fiscal years ending March 2022 through March 2023 because it is difficult to calculate them reasonably.」
Due to the impact of COVID-19, publication of the earnings forecast for the following fiscal year and the numerical plans for the fiscal years ending March 2022 through March 2023 was postponed, leaving the company temporarily without specific growth targets. - FY2019SoftenedAnnual report
「Basic policy: promote the development of new products, innovation in production technology and stronger sales capabilities to further advance the use of regenerative medicine.」
Compared with the previously disclosed targets of revenue of ¥3,481 million and operating profit of ¥329 million for the fiscal year ending March 2020, and revenue of ¥4,042 million and operating profit of ¥302 million for the fiscal year ending March 2021, the current plan lowered the targets to revenue of ¥3,080 million and operating profit of ¥106 million for the fiscal year ending March 2020, and revenue of ¥3,589 million and operating profit of ¥207 million for the fiscal year ending March 2021, while newly adding a target for the fiscal year ending March 2022. - FY2018First statedAnnual report
「Basic policy: strengthen the foundation for sustained profitability while accelerating development for future growth. ① Sustainably expand sales of existing products. ② Accelerate new product development and grow the contract services business. ③ Further improve management efficiency. Fiscal year ending March 2020 (target): revenue ¥3,481 million, operating profit ¥329 million, operating margin 9.5%. Fiscal year ending March 2021 (target): revenue ¥4,042 million, operating profit ¥302 million, operating margin 7.5%.」
The company set strengthening the foundation for sustained profitability as its basic policy and, for the first time, presented specific targets for revenue, operating profit and operating margin for the fiscal years ending March 2020 and March 2021, using existing products, new products and the contract services business, and efficiency improvements as the means of achieving them.